A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and Probationers

Donna M. Coviello, James W. Cornish, Kevin G. Lynch, Tamara Y. Boney, Cynthia A. Clark, Joshua D. Lee, Peter D. Friedmann, Edward V. Nunes, Timothy W. Kinlock, Michael S. Gordon, Robert P. Schwartz, Elie S. Nuwayser, Charles P. O'Brien

Research output: Contribution to journalArticlepeer-review

Abstract

A feasibility study was conducted to pilot test the ability of 5 sites to recruit, treat, and retain opioid-dependent offenders in a trial of extended-release injectable naltrexone (XR-NTX). The participants, 61 previously opioid-dependent individuals under legal supervision in the community, received up to 6 monthly injections of Depotrex brand naltrexone and completed a 6-month follow-up interview. Six-month outcomes showed that those who completed treatment had significantly fewer opioid-positive urines and were less likely to have been incarcerated than those who had not completed treatment. The findings indicate that XR-NTX holds promise as a feasible, effective treatment option for opioid-dependent offenders.

Original languageEnglish (US)
Pages (from-to)48-59
Number of pages12
JournalSubstance Abuse
Volume33
Issue number1
DOIs
StatePublished - Jan 1 2012

Keywords

  • Depotrex
  • Extended-release naltrexone
  • addiction pharmacotherapy
  • heroin
  • offenders
  • opioid dependence

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and Probationers'. Together they form a unique fingerprint.

Cite this